Drug intelligence / Profile preview

Trinity Elite

Development stage: Unknown
Lead developer: Orthofix
Modality: Cell Therapies
Administration: Implant

Overview

**Trinity Elite** is a cryopreserved, viable cellular bone allograft for surgical implantation to treat musculoskeletal bone defects and support bone fusion procedures, including lumbar spinal fusion. The donated human-tissue graft contains cancellous bone, demineralized cortical bone fibers, viable adult mesenchymal stem cells, osteoprogenitor cells, osteoblasts, and endogenous osteoinductive factors. It is intended as a moldable autograft substitute that provides an osteoconductive scaffold, osteogenic cells, and osteoinductive signaling to support new bone formation. Trinity Elite is commercialized by Orthofix and exclusively processed by MTF Biologics.

Brand names: Trinity ELITE
Other names: Trinity Elite cellular allograftTrinity Elite cellular bone allograft

Beyond the preview

Go deeper on Trinity Elite.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trinity Elite.

Explore the full profile